Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery

BACKGROUND: Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the treatment of diabetes, its large molecular weight and high hydrophilicity result in poor cellular permeability, thus limiting its oral bioavailability. To address this, we developed a chimeric GLP-1A that target...

Descripción completa

Detalles Bibliográficos
Autores principales: Kweon, Seho, Lee, Jun-Hyuck, Yang, Seong-Bin, Park, Seong Jin, Subedi, Laxman, Shim, Jung-Hyun, Cho, Seung-Sik, Choi, Jeong Uk, Byun, Youngro, Park, Jooho, Park, Jin Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474648/
https://www.ncbi.nlm.nih.gov/pubmed/37660070
http://dx.doi.org/10.1186/s40824-023-00421-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474648/
https://www.ncbi.nlm.nih.gov/pubmed/37660070
http://dx.doi.org/10.1186/s40824-023-00421-7

Ejemplares similares